What is the FDA’s regulatory framework for COVID-19 vaccination?
On May 20, 2025, the FDA published an updated policy position in the New England Journal of Medicine on an evidence-based approach to COVID-19 vaccination.
The following patient populations are at elevated risk for severe outcomes from COVID-19 infection:
- Adults aged 65 years or older
- Individuals ages 6 months or older with one or more underlytingh condfitions that puts theme at high risk for severe COVID-19 outcomes.
You can see the list of underlying conditions that increase the risk of severe COVID-19 by clicking here.